<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Health Canada</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Health Canada vows to streamline operations for device, drug makers</title>
      <description>
        <![CDATA[Health Canada posted a report on reduction of red tape, which includes a proposal for mutual recognition of other regulators’ inspections of device and drug manufacturing facilities.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724202</guid>
      <pubDate>Fri, 12 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724202-health-canada-vows-to-streamline-operations-for-device-drug-makers</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Canada/Health-Canada-Sign.webp?t=1757623393" type="image/png" medium="image" fileSize="2341398">
        <media:title type="plain">Health Canada office sign</media:title>
        <media:description type="plain">Credit: JHVEPhoto</media:description>
      </media:content>
    </item>
    <item>
      <title>Health Canada vows to streamline operations for device, drug makers</title>
      <description>
        <![CDATA[Health Canada posted a report on reduction of red tape, which includes a proposal for mutual recognition of other regulators’ inspections of device and drug manufacturing facilities.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723735</guid>
      <pubDate>Thu, 11 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723735-health-canada-vows-to-streamline-operations-for-device-drug-makers</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Canada/Health-Canada-Sign.webp?t=1757623393" type="image/png" medium="image" fileSize="2341398">
        <media:title type="plain">Health Canada office sign</media:title>
        <media:description type="plain">Credit: JHVEPhoto</media:description>
      </media:content>
    </item>
    <item>
      <title>Proteinqure’s PQ-203 cleared to enter clinic in US and Canada</title>
      <description>
        <![CDATA[Proteinqure Inc. has received regulatory clearances from the U.FDA and Health Canada to initiate a phase I trial of lead candidate, PQ-203. The trial will begin in Canada and expand to U.S. sites later in 2025. The FDA also granted PQ-203 fast track designation for triple-negative breast cancer (TNBC).]]>
      </description>
      <guid>http://www.bioworld.com/articles/723061</guid>
      <pubDate>Fri, 08 Aug 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723061-proteinqures-pq-203-cleared-to-enter-clinic-in-us-and-canada</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Breast-cancer-illustration.webp?t=1755012743" type="image/jpeg" medium="image" fileSize="458149">
        <media:title type="plain">Breast cancer illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Abcellera gains Canadian clearance for phase I study of ABCL-635 for vasomotor symptoms in menopause</title>
      <description>
        <![CDATA[Abcellera Biologics Inc. has received a no objection letter from Health Canada authorizing its clinical trial application (CTA) for ABCL-635.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720212</guid>
      <pubDate>Thu, 15 May 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720212-abcellera-gains-canadian-clearance-for-phase-i-study-of-abcl-635-for-vasomotor-symptoms-in-menopause</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Sexual-health/womens-health-doctor.webp?t=1747320873" type="image/jpeg" medium="image" fileSize="574220">
        <media:title type="plain">Woman at doctors office visit</media:title>
      </media:content>
    </item>
    <item>
      <title>Health Canada jumps into PCCP filings for machine learning</title>
      <description>
        <![CDATA[The world of machine learning-enabled medical technology is advancing rapidly, and regulators are struggling to keep up, and Health Canada has joined the ranks of regulators who are tackling these technologies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/717713</guid>
      <pubDate>Tue, 04 Mar 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/717713-health-canada-jumps-into-pccp-filings-for-machine-learning</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Canada/thumb/canada-court-regulatory.webp?t=1572450578" type="image/png" medium="image" fileSize="241526">
        <media:title type="plain">canada-court-regulatory.png</media:title>
      </media:content>
    </item>
    <item>
      <title>Neuralink just one part of ongoing BCI evolution</title>
      <description>
        <![CDATA[Fifty years after the term brain-computer interface (BCI) was coined, Neuralink and several other companies are reviving the promise of BCI for health care, as artificial intelligence and novel methods of neural signal detection work hand-in-hand to propel biomedical innovation. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/714499</guid>
      <pubDate>Tue, 26 Nov 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/714499-neuralink-just-one-part-of-ongoing-bci-evolution</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/brain-computer-interface-chip-digital-AI.webp?t=1745264159" type="image/jpeg" medium="image" fileSize="236898">
        <media:title type="plain">Illustration of head with circuit board brain</media:title>
      </media:content>
    </item>
    <item>
      <title>Organox gets greenlight in Canada for liver transplantation system</title>
      <description>
        <![CDATA[Organox Ltd. gained approval from Health Canada for its Metra system for use during liver transplantation. The system utilizes normothermic machine perfusion to maintain donor livers under physiologic conditions prior to transplantation.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712704</guid>
      <pubDate>Fri, 04 Oct 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712704-organox-gets-greenlight-in-canada-for-liver-transplantation-system</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-on-digital-lens.webp?t=1709588066" type="image/jpeg" medium="image" fileSize="175206">
        <media:title type="plain">Liver over digital lens background</media:title>
      </media:content>
    </item>
    <item>
      <title>Palisade submits CTA for PDE4 inhibitor prodrug for ulcerative colitis </title>
      <description>
        <![CDATA[Palisade Bio Inc. has submitted a clinical trial application (CTA) for PALI-2108 for the treatment of ulcerative colitis, following a pre-CTA consultation meeting with Health Canada. Pending clearance, the company anticipates initiating a phase I study by year-end.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712825</guid>
      <pubDate>Thu, 26 Sep 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712825-palisade-submits-cta-for-pde4-inhibitor-prodrug-for-ulcerative-colitis</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/IBD-ulcerative-colitis.webp?t=1668182386" type="image/png" medium="image" fileSize="1246429">
        <media:title type="plain">Gastrointestinal system with ulcerative colitis.</media:title>
      </media:content>
    </item>
    <item>
      <title>Trio of regulators issues guidelines for transparency for AI</title>
      <description>
        <![CDATA[For the third time in as many years, Health Canada, the U.S. FDA and the UK Medicines and Health Care Products Regulatory Agency have teamed up to issue a set of recommendations for artificial intelligence used in or as a medical device.]]>
      </description>
      <guid>http://www.bioworld.com/articles/709461</guid>
      <pubDate>Mon, 17 Jun 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/709461-trio-of-regulators-issues-guidelines-for-transparency-for-ai</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Gears-with-words.webp?t=1701979068" type="image/jpeg" medium="image" fileSize="381498">
        <media:title type="plain">Gears with regulatory words</media:title>
      </media:content>
    </item>
    <item>
      <title>Canada continues to voice concerns about US drug imports</title>
      <description>
        <![CDATA[The U.S. FDA’s Jan. 5 approval of Florida’s plan to import prescription drugs from Canada to take advantage of their lower price triggered ongoing communication between senior U.S. officials and Canada’s Ministry of Health over Canadian concerns about maintaining sufficient drug supplies. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/704769</guid>
      <pubDate>Wed, 17 Jan 2024 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/704769-canada-continues-to-voice-concerns-about-us-drug-imports</link>
    </item>
    <item>
      <title>US FDA importation approval: Worth the wait?</title>
      <description>
        <![CDATA[With its approval Jan. 5 of Florida’s drug importation program, the U.S. FDA ended a 23-year wait for the government to implement a 2000 provision allowing certain prescription drug imports from Canada.]]>
      </description>
      <guid>http://www.bioworld.com/articles/704411</guid>
      <pubDate>Mon, 08 Jan 2024 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/704411-us-fda-importation-approval-worth-the-wait</link>
    </item>
    <item>
      <title>Canada launches new drug agency</title>
      <description>
        <![CDATA[In an effort to standardize prescription practices across Canada, help Canadians afford their medicines and improve access to health data, the government is investing an additional $89.5 million over the next five years to establish the Canadian Drug Agency.]]>
      </description>
      <guid>http://www.bioworld.com/articles/704017</guid>
      <pubDate>Wed, 20 Dec 2023 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/704017-canada-launches-new-drug-agency</link>
    </item>
    <item>
      <title>Ankyra Therapeutics receives clearance in US and Canada to advance its anchored immunotherapy agent into clinical trials </title>
      <description>
        <![CDATA[Ankyra Therapeutics Inc. has received approval of its IND application by the FDA and its clinical trial application (CTA) by Health Canada for its lead agent, ANK-101, a novel tumor-directed anchored immune medicine.]]>
      </description>
      <guid>http://www.bioworld.com/articles/702191</guid>
      <pubDate>Wed, 25 Oct 2023 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/702191-ankyra-therapeutics-receives-clearance-in-us-and-canada-to-advance-its-anchored-immunotherapy-agent-into-clinical-trials</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/NCI-Tumor-Microenvironment.webp?t=1668701295" type="image/png" medium="image" fileSize="536658">
        <media:title type="plain">Tumor microenvironment</media:title>
        <media:description type="plain">A traditional view of the tumor microenvironment (TME). Neurons are increasingly being recognized as an important part of the TME in many cancer types. Credit: NCI</media:description>
      </media:content>
    </item>
    <item>
      <title>Tetra Bio-Pharma's oral ARDS-003 cleared by Health Canada to enter clinic</title>
      <description>
        <![CDATA[Tetra Bio-Pharma Inc. has received clearance from Health Canada to proceed with a first-in-human trial in Canada using oral ARDS-003 (onternabez) to treat various immunomodulatory conditions. Oral ARDS-003 is positioned to modulate acute systemic inflammation and prevent sepsis, acute respiratory distress syndrome (ARDS) and organ damage.]]>
      </description>
      <guid>http://www.bioworld.com/articles/695044</guid>
      <pubDate>Mon, 13 Mar 2023 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/695044-tetra-bio-pharmas-oral-ards-003-cleared-by-health-canada-to-enter-clinic</link>
    </item>
    <item>
      <title>Health Canada lays out the rules for psychedelics in treatment</title>
      <description>
        <![CDATA[In light of the growing interest in the use of psilocybin, MDMA and other psychedelics in psychotherapy, Health Canada issued a notice spelling out how licensed providers can obtain the drugs through the agency’s special access program on a case-by-case basis. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/694677</guid>
      <pubDate>Tue, 28 Feb 2023 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/694677-health-canada-lays-out-the-rules-for-psychedelics-in-treatment</link>
    </item>
    <item>
      <title>Canadian clearance for phase I trial of Lucid-MS for multiple sclerosis</title>
      <description>
        <![CDATA[FSD Pharma Inc. has received a no objection letter (NOL) from Health Canada granting regulatory approval to commence a phase I trial of LUCID-21-302 (Lucid-MS), a novel drug candidate for the treatment of multiple sclerosis (MS).]]>
      </description>
      <guid>http://www.bioworld.com/articles/694050</guid>
      <pubDate>Wed, 08 Feb 2023 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/694050-canadian-clearance-for-phase-i-trial-of-lucid-ms-for-multiple-sclerosis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Multiple-sclerosis.webp?t=1607460204" type="image/png" medium="image" fileSize="446686">
        <media:title type="plain">Multiple sclerosis</media:title>
      </media:content>
    </item>
    <item>
      <title>Amylyx counts on new analyses as it heads into second US adcom</title>
      <description>
        <![CDATA[Amylyx Pharmaceuticals Inc.’s amyotrophic lateral sclerosis candidate, AMX-0035, will get a rare second bite at the adcom apple Sept. 7. This time around, the Cambridge, Mass.-based company is looking to improve on its first performance by stressing the survival benefit of its drug.]]>
      </description>
      <guid>http://www.bioworld.com/articles/689358</guid>
      <pubDate>Tue, 06 Sep 2022 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/689358-amylyx-counts-on-new-analyses-as-it-heads-into-second-us-adcom</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Musculoskeletal/Person-using-walker.webp?t=1745262568" type="image/jpeg" medium="image" fileSize="193541">
        <media:title type="plain">Person using walker </media:title>
      </media:content>
    </item>
    <item>
      <title>ACIP blesses bivalent vaccines for US market</title>
      <description>
        <![CDATA[In the hope of preventing thousands of hospitalizations and deaths over the next few months, the U.S. CDC’s Advisory Committee on Immunization Practice (ACIP) voted 13-1 Sept. 1 to recommend the use of Moderna Inc.’s and Pfizer Inc.-Biontech SE’s updated vaccines that contain components of both the original SARS-CoV-2 virus and the omicron BA.4/5 subvariants as boosters.]]>
      </description>
      <guid>http://www.bioworld.com/articles/672674</guid>
      <pubDate>Thu, 01 Sep 2022 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/672674-acip-blesses-bivalent-vaccines-for-us-market</link>
    </item>
    <item>
      <title>Good news for Amylyx as it prepares for adcom redux</title>
      <description>
        <![CDATA[Amylyx Pharmaceuticals Inc. got good news when the Institute for Clinical and Economic Review posted a revised evidence report Aug. 4 that assessed the comparative clinical effectiveness and value of the company’s AMX-0035 and Mitsubishi Tanabe Pharma America Inc.’s Radicava (edaravone) in treating amyotrophic lateral sclerosis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/521341</guid>
      <pubDate>Thu, 04 Aug 2022 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/521341-good-news-for-amylyx-as-it-prepares-for-adcom-redux</link>
    </item>
    <item>
      <title>2022 to be the year of draft guidances for AI and machine learning</title>
      <description>
        <![CDATA[Much of the question of FDA regulation of artificial intelligence (AI) and machine learning (ML) is seen as revolving around changes to the statute, but that does not mean the FDA and other agencies are in wait-and-see mode. Representatives of both the FDA and Health Canada said on a March 22 webinar that guidances related to these algorithms will be posted later this year, thus opening the door to a more predictable premarket path for these products.]]>
      </description>
      <guid>http://www.bioworld.com/articles/517197</guid>
      <pubDate>Tue, 22 Mar 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/517197-2022-to-be-the-year-of-draft-guidances-for-ai-and-machine-learning</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/AI/AI-digital-health.webp?t=1683125967" type="image/jpeg" medium="image" fileSize="229937">
        <media:title type="plain">Artificial intelligence and digital health icons</media:title>
      </media:content>
    </item>
    <item>
      <title>Vena Medical catheter gets up close to remove intracranial blood clots on first try</title>
      <description>
        <![CDATA[Vena Medical Inc. received Health Canada approval for a device that combines two neurovascular catheters that typically work separately to remove clots from the brains of people who have suffered stroke.]]>
      </description>
      <guid>http://www.bioworld.com/articles/516643</guid>
      <pubDate>Thu, 03 Mar 2022 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/516643-vena-medical-catheter-gets-up-close-to-remove-intracranial-blood-clots-on-first-try</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/03-02-Vena-BGC.webp?t=1646348572" type="image/png" medium="image" fileSize="572840">
        <media:title type="plain">Device illustration</media:title>
        <media:description type="plain">The Vena BDAC (Balloon Distal Access Catheter) combines balloon guide and distal access catheters to remove small blood clots in the brain that are hard to access and remove.</media:description>
      </media:content>
    </item>
    <item>
      <title>Mitsubishi, GSK harvest plant-based COVID-19 vaccine win in Canada</title>
      <description>
        <![CDATA[With the first global approval by Health Canada in hand, Medicago Inc. aims to provide 20 million doses this year of Covifenz – which itself represents another first, as a plant-originated, virus-like particle, recombinant, adjuvanted COVID-19 vaccine. “Hopefully, if all goes well, we’ll be able to do it faster than the last day of the last month” of the year, said Brian Ward, medical officer of Quebec City-based Medicago, a unit of Mitsubishi Tanabe Pharma Corp., which partnered on Covifenz with Glaxosmithkline plc (GSK).]]>
      </description>
      <guid>http://www.bioworld.com/articles/516552</guid>
      <pubDate>Tue, 01 Mar 2022 10:15:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/516552-mitsubishi-gsk-harvest-plant-based-covid-19-vaccine-win-in-canada</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/thumb/COVID-19-vaccine-and-syringe-with-flag-of-China.webp?t=1645570384" type="image/png" medium="image" fileSize="242075">
        <media:title type="plain">COVID-19 vaccine and syringe with flag of China</media:title>
      </media:content>
    </item>
    <item>
      <title>Mitsubishi, GSK harvest plant-based COVID-19 vaccine win in Canada</title>
      <description>
        <![CDATA[With the first global approval by Health Canada in hand, Medicago Inc. aims to provide 20 million doses this year of Covifenz – which itself represents another first, as a plant-originated, virus-like particle, recombinant, adjuvanted COVID-19 vaccine. “Hopefully, if all goes well, we’ll be able to do it faster than the last day of the last month” of the year, said Brian Ward, medical officer of Quebec City-based Medicago, a unit of Mitsubishi Tanabe Pharma Corp., which partnered on Covifenz with Glaxosmithkline plc (GSK).]]>
      </description>
      <guid>http://www.bioworld.com/articles/516394</guid>
      <pubDate>Thu, 24 Feb 2022 10:15:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/516394-mitsubishi-gsk-harvest-plant-based-covid-19-vaccine-win-in-canada</link>
    </item>
    <item>
      <title>Hyperfine’s MRI ‘swoops’ into Canadian market following Health Canada approval</title>
      <description>
        <![CDATA[TORONTO – Hyperfine Inc. has received Health Canada approval for the first FDA-cleared portable magnetic resonance imaging (MRI) device, which also features advanced reconstruction deep learning software. The company simultaneously announced its commercial launch of the Swoop imaging system in Canada.]]>
      </description>
      <guid>http://www.bioworld.com/articles/514375</guid>
      <pubDate>Fri, 17 Dec 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/514375-hyperfines-mri-swoops-into-canadian-market-following-health-canada-approval</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/12-17-Hyperfine-Swoop-patient.webp?t=1639781853" type="image/png" medium="image" fileSize="1650593">
        <media:title type="plain">Swoop being used on a patient</media:title>
        <media:description type="plain">The Swoop system reimagines access to magnetic resonance imaging. Credit: Hyperfine Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Medicago poised to seek approval for plant-based COVID-19 vaccine</title>
      <description>
        <![CDATA[Mitsubishi Tanabe Pharma Corp.'s Medicago Inc. plans to "imminently" seek Health Canada approval for its plant-based COVID-19 vaccine candidate, MT-2766, after top-line phase III results showed an overall vaccine efficacy rate of 71% against all variants of SARS-CoV-2.]]>
      </description>
      <guid>http://www.bioworld.com/articles/514048</guid>
      <pubDate>Tue, 07 Dec 2021 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/514048-medicago-poised-to-seek-approval-for-plant-based-covid-19-vaccine</link>
    </item>
    <item>
      <title>Canada approves Koios’s AI-driven, breast cancer ultrasound software</title>
      <description>
        <![CDATA[TORONTO – Koios Medical Inc. has received Health Canada approval for its DS Smart Ultrasound decision support software, which the company said accurately interprets breast ultrasound examinations. Company CEO Chad McClennan told <em>BioWorld</em> greater accuracy will provide early cancer detection rates, while reducing costly false positives and unnecessary biopsies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/513884</guid>
      <pubDate>Wed, 01 Dec 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/513884-canada-approves-koioss-ai-driven-breast-cancer-ultrasound-software</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cell-under-magnifying-glass.webp?t=1611092780" type="image/png" medium="image" fileSize="453785">
        <media:title type="plain">Cancer cells under magnifying glass</media:title>
      </media:content>
    </item>
    <item>
      <title>Emergent facility back in international COVID-19 vaccine supply chain</title>
      <description>
        <![CDATA[Emergent Biosolutions Inc.’s Bayview facility in Baltimore passed its manufacturing inspection with international regulators, clearing the way for shipment of batches of Johnson & Johnson’s (J&J) COVID-19 vaccine containing drug substance made at the plant.]]>
      </description>
      <guid>http://www.bioworld.com/articles/513712</guid>
      <pubDate>Wed, 24 Nov 2021 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/513712-emergent-facility-back-in-international-covid-19-vaccine-supply-chain</link>
    </item>
    <item>
      <title>FDA teams up with authorities in UK, Canada on GMLPs</title>
      <description>
        <![CDATA[The world of artificial intelligence (AI) regulation is still in its infancy, but a number of agencies are nonetheless keen on harmonization for at least some of this policymaking task. The FDA announced recently that it has joined with Health Canada and the U.K. Medicines and Healthcare Products Regulatory Agency to develop a series of 10 guiding principles for good machine learning practices (GMLP), thus answering one of the key questions facing developers of these algorithms.]]>
      </description>
      <guid>http://www.bioworld.com/articles/512890</guid>
      <pubDate>Fri, 29 Oct 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/512890-fda-teams-up-with-authorities-in-uk-canada-on-gmlps</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Puzzle-pieces-globe.webp?t=1588276858" type="image/png" medium="image" fileSize="696324">
        <media:title type="plain">Hands holding puzzle pieces with digital globe overlay</media:title>
      </media:content>
    </item>
    <item>
      <title>Voxneuro cognitive platform to launch following Canadian and FDA approvals</title>
      <description>
        <![CDATA[TORONTO &ndash; Western New York Imaging Group, a one-hour drive across the U.S.-Canadian border, will soon be the site for a hard launch of Champ, a system developed by Voxneuro Inc. that evaluates suspected cognitive brain disorder or symptoms such as fatigue, memory loss or brain fog. This comes after Voxneuro won FDA registration of the cognitive platform as a class II exempt medical license, followed last month by Health Canada approval of the system for help diagnosing concussion, traumatic brain injury and dementia.]]>
      </description>
      <guid>http://www.bioworld.com/articles/510436</guid>
      <pubDate>Fri, 13 Aug 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/510436-voxneuro-cognitive-platform-to-launch-following-canadian-and-fda-approvals</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/08-13-Voxneuro.webp?t=1628886033" type="image/png" medium="image" fileSize="1605980">
        <media:title type="plain">Patient undergoing cognitive testing with Champ</media:title>
        <media:description type="plain">The Champ platform scores four key cognitive functions: memory, information processing, attention and concentration, helping physicians diagnose serious brain disorders. Credit: Voxneuro Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Health Canada likes what it sees in Sievrt VR radiology platform</title>
      <description>
        <![CDATA[TORONTO &ndash; Health Canada has green-lighted an all-in-one virtual reality (VR) platform for use in diagnostic radiology. Software developer Luxsonic Technologies Inc. said the award of a class II medical device license to its mobile Sievrt suite of diagnostic tools is the first time a VR system of this kind has been approved by a national regulatory agency.]]>
      </description>
      <guid>http://www.bioworld.com/articles/510207</guid>
      <pubDate>Fri, 06 Aug 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/510207-health-canada-likes-what-it-sees-in-sievrt-vr-radiology-platform</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/08-06-Luxsonic-SieVRt-Screenshot-MedED-Case-FPV-7.webp?t=1628285667" type="image/png" medium="image" fileSize="655922">
        <media:title type="plain">Sample rendering of Sievrt</media:title>
        <media:description type="plain">Through its headset-based VR environment, the Sievrt platform creates a 3D space in which radiologists can manipulate objects and even control lighting within the VR room.</media:description>
      </media:content>
    </item>
  </channel>
</rss>
